InvestWiser

Cereno Scientific AB Series B

CRNO-BNasdaq StockholmHealthcareMarket value 58 m SEK
0.18SEK +13.4%
last day · Price as of 19 November 2026

The answer first

Does Cereno Scientific beat the market?

No, Cereno Scientific has not beaten the market over the last year.

Cereno Scientific−97.2%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 19% of Nordic stocks

    • Quality52
    • Value50
    • Trend2

    No. 134 of 195 in healthcare

Max for seven days

Follow Cereno Scientific with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Cereno Scientific

From today, at a price of 0.18 SEK. Write why you follow Cereno Scientific, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Cereno Scientific

Your first answer is free, no account needed.

Do you own Cereno Scientific, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Cereno Scientific and a few more. Free, no card.

Past year against the exchange and Super Stock
Cereno Scientific−97.4%Stockholm (OMXSGI)+17.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Cereno Scientific has fallen 97.2% over the past year, including dividends.
  • Overall, Cereno Scientific ranks better than 19% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 98.8%. The price is 98.5% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

19

Quality, value and trend together. Better than 19% of Nordic stocks.

No. 134 of 195 in healthcare

Quality52
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 125 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.76
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−57.0%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value50
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 53 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.2
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend2
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 188 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−96.1%
  • 6 months−96.8%
  • 9 months−97.3%
  • 12 months−97.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−94.3%
3 years, per year
−65.2%
5 years, per year
−49.0%
10 years, per year
−30.2%
Largest fall, 3 years
−98.8%
From a peak to the bottom
From the peak now
−98.5%
How far the price is from the peak
Volatility, 1 year
115.6%
How much the price swings over a year
Beta, 1 year
0.56
How much the price moves when the market moves

Return with dividends reinvested.

About Cereno Scientific

Cereno Scientific AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms.

See the full analysis of Cereno Scientific.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market